Results

What is the CIC achieving?

  • identifying potential therapies
  • partnering with industry
  • supporting small biotech companies
  • facilitating investment decisions
  • publishing novel data
  • expanding capacity
Since 2005, the CIC has risen to prominence as a leader in research and related drug development for asthma and other airways diseases.

In collaboration with industry scientists, CIC delivers highly sought-after, niche clinical trial services to large and small pharmaceutical, biotech and biopharma companies. CIC has established major, ongoing industrial partnerships with biopharmaceutical companies including Amgen, AstraZeneca, Genentech, Novartis, Pfizer, Schering Plough, and Wyeth, and with small biotechnological companies from Canada and the USA.

The CIC has put Canada on the map as a leader in research and related drug development for asthma and other airways diseases.

.
Image is not available
Image is not available

Identifying potential therapies

Identifying potential therapies

Identifying potential therapies

Partnering with industry

Partnering with industry

Partnering with industry

Image is not available

Facilitating investment decisions

Facilitating investment decisions

Facilitating investment decisions

Image is not available

Publishing novel data

Publishing novel data

Publishing novel data

Image is not available

Supporting small biotech companies

Supporting small biotech companies

Supporting small biotech companies

Image is not available

Expanding capacity

Expanding capacity

Expanding capacity

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Drug candidates
Quilizumab & Mepolizumab
CIC identified effective new molecule candidates for future investment, including ligelizumab (Novartis) for chronic spontaneous urticaria. Quilizumab (Genentech) and tezepelumab (Amgen) moved into phase II testing.

Identifying potential therapies

Identifying potential therapies

Identifying potential therapies

Image is not available

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Partnerships
CIC has partnered with 17 companies, including: AIM Therapeutics, Alexion Pharmaceuticals, Altair Pharmaceuticals, Amgen, Asmacure, AstraZeneca, Axikin Pharmaceuticals, Boehringer Ingelheim, Genentech, IVAX, MedImmune, Novartis, ONO Pharmaceutical, Schering-Plough, Topigen Pharmaceuticals, and Wyeth.
Evaluating Compounds

Partnering with industry

Partnering with industry

Partnering with industry

Image is not available

Therapies

Therapies

Therapies

Therapies

Therapies

Partners

Partners

Investment decisions

Investment decisions

Publications

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Discovery Investments
CIC trials have allowed companies to prioritize their discovery investments with small, effective studies, and validated models that are 100% accurate for making “no-go” decisions.

Facilitating investment decisions

Facilitating investment decisions

Facilitating investment decisions

Image is not available

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Image is not available
Topigen Pharmaceuticals
CIC facilitated the success of Canadian start-up biotechnology company, Topigen Pharmaceuticals, by demonstrating the efficacy and target knock-down by the drug ASM08, resulting in Topigen's acquisition by Pharmaxis.

Supporting small biotech companies

Supporting small biotech companies

Supporting small biotech companies

Image is not available
Commercialization insights
CIC provided new Canadian biotechnology companies (Asmacure, AIM Therapeutics) with business and commercialization insights on which they based strategic investment decisions.

Therapies

Partners

Investment decisions

Publications

Biotech support

Home

Slider

WordPress Image Lightbox